Forecyte Bio and Cytiva to Collaborate on Cell and Gene Therapy Manufacturing and Development
Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.
Cytiva and Forecyte Bio announced on August 25, 2022 that they will collaborate to accelerate the manufacturing and development of the cell and gene therapy industry in China and the United States.
The companies will utilize Cytiva’s Fast Trak center in Shanghai, where biotech companies can access industry knowledge and professional consulting and training. Forectye Bio will use the Shanghai facility and Cytiva’s FlexFactory platforms to launch its contract development and manufacturing organization (CDMO) business and have good manufacturing practice (GMP) production capabilities for virus and plasmid DNA.
"Cytiva’s end-to-end solutions and customer-centric mindset are the foundation of this collaboration,” said Lihua Yu, general manager of Cytiva in Greater China, in a company press release. “Our vision is a world in which access to life-changing therapies transforms human health. I believe that the collaboration with Forecyte Bio will lead us one step closer to this.”
“The collaboration will accelerate the standardization of processes in the CGT CDMO and promote the development of the industry. It will also help us offer a ‘one-stop’ holistic service package to clients and ultimately improve patient access to cell and gene therapies,” added Yingke He, founder and CEO of Forecyte Bio, in the release.
Source: Cytiva
